Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 30,788 Shares of Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $11.81, for a total transaction of $363,606.28. Following the sale, the insider now owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Neumora Therapeutics Trading Up 4.3 %

NMRA stock opened at $12.73 on Friday. Neumora Therapeutics, Inc. has a 12-month low of $8.33 and a 12-month high of $21.00. The business’s 50-day moving average is $11.70 and its 200 day moving average is $11.48.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.37). Research analysts expect that Neumora Therapeutics, Inc. will post -1.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $29.00 target price on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Neumora Therapeutics in a report on Thursday, September 12th. Finally, Mizuho began coverage on Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $22.11.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank acquired a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $29,000. Quarry LP purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at about $98,000. SkyOak Wealth LLC acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at about $147,000. Principal Financial Group Inc. purchased a new position in Neumora Therapeutics in the 2nd quarter worth approximately $166,000. Finally, SG Americas Securities LLC acquired a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $566,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.